Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
Volc D, Poewe W, Kutzelnigg A, Lührs P, Thun-Hohenstein C, Schneeberger A, Galabova G, Majbour N, Vaikath N, El-Agnaf O, Winter D, Mihailovska E, Mairhofer A, Schwenke C, Staffler G, Medori R. Volc D, et al. Lancet Neurol. 2020 Jul;19(7):591-600. doi: 10.1016/S1474-4422(20)30136-8. Lancet Neurol. 2020. PMID: 32562684 Clinical Trial.
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.
Poewe W, Volc D, Seppi K, Medori R, Lührs P, Kutzelnigg A, Djamshidian A, Thun-Hohenstein C, Meissner WG, Rascol O, Schneeberger A, Staffler G; AFF011 investigators; AFF011 study investigators:; Poewe W, Seppi K, Djamshidian A, deMarzi R, Heim B, Mangesius S, Stolz R, Wachowicz K, Volc D, Thun-Hohenstein C, Riha C, Schneeberger A, Bürger V, Galabova G. Poewe W, et al. Among authors: volc d. J Parkinsons Dis. 2021;11(3):1079-1089. doi: 10.3233/JPD-212594. J Parkinsons Dis. 2021. PMID: 34092654 Free PMC article. Clinical Trial.
Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.
Przuntek H, Bittkau S, Bliesath H, Büttner U, Fuchs G, Glass J, Haller H, Klockgether T, Kraus P, Lachenmayer L, Müller D, Müller T, Rathay B, Sgonina J, Steinijans V, Teshmar E, Ulm G, Volc D. Przuntek H, et al. Among authors: volc d. Arch Neurol. 2002 May;59(5):803-6. doi: 10.1001/archneur.59.5.803. Arch Neurol. 2002. PMID: 12020263 Clinical Trial.
A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.
Meissner WG, Traon AP, Foubert-Samier A, Galabova G, Galitzky M, Kutzelnigg A, Laurens B, Lührs P, Medori R, Péran P, Sabatini U, Vergnet S, Volc D, Poewe W, Schneeberger A, Staffler G, Rascol O; AFF009 Study Investigators. Meissner WG, et al. Among authors: volc d. Mov Disord. 2020 Nov;35(11):1957-1965. doi: 10.1002/mds.28218. Epub 2020 Sep 3. Mov Disord. 2020. PMID: 32882100 Free PMC article. Clinical Trial.
Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O'Gorman J, Haeberlein SB; PASSPORT Study Group. Dam T, et al. Nat Med. 2023 Nov;29(11):2955-2956. doi: 10.1038/s41591-022-02076-8. Nat Med. 2023. PMID: 36253611 Free article. No abstract available.
Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease.
Mahlknecht P, Pechlaner R, Boesveldt S, Volc D, Pinter B, Reiter E, Müller C, Krismer F, Berendse HW, van Hilten JJ, Wuschitz A, Schimetta W, Högl B, Djamshidian A, Nocker M, Göbel G, Gasperi A, Kiechl S, Willeit J, Poewe W, Seppi K. Mahlknecht P, et al. Among authors: volc d. Mov Disord. 2016 Sep;31(9):1408-13. doi: 10.1002/mds.26637. Epub 2016 May 9. Mov Disord. 2016. PMID: 27159493 Free PMC article. Review.
23 results